Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

EarningsARCALYSTKPL-387Positive

AI Analysis

Summary

Kiniksa Pharmaceuticals reported Q2 2026 ARCALYST net product revenue of $243.6 million with ~55% year-over-year growth and raised full-year guidance to $980-$995 million. KPL-387 demonstrated positive Phase 2 data in pain and inflammation reduction and has advanced to Phase 3 enrollment in recurrent pericarditis.

Clinical Trial Data

Phase

Phase 3

Financial Highlights

Revenue

$243.6 million (ARCALYST Q2 2026)

Guidance

$980 - $995 million (ARCALYST 2026 expected net product revenue)

Importance:7/10

Sentiment:

0.80

earningsrevenue growthPhase 2 positive dataPhase 3 enrollmentguidance raise

Related Companies

$KNSA

Read the original article

Published by GlobeNewswire Pharma on July 28, 2026 11:30 AM

Read Original